Publicaciones en colaboración con investigadores/as de Hôpital Notre-Dame (22)

2022

  1. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

    PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339

2018

  1. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

    Multiple Sclerosis Journal, Vol. 24, Núm. 5, pp. 642-652

2017

  1. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

    Neurology, Vol. 89, Núm. 10, pp. 1050-1059

  2. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 88, Núm. 3, pp. 196-203

  3. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1346-1357

  4. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

    Brain, Vol. 140, Núm. 9, pp. 2426-2443

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

  2. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

    Multiple Sclerosis, Vol. 22, Núm. 4, pp. 520-532

2015

  1. BREMSO: A simple score to predict early the natural course of multiple sclerosis

    European Journal of Neurology, Vol. 22, Núm. 6, pp. 981-989

  2. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

    Multiple Sclerosis, Vol. 21, Núm. 9, pp. 1159-1171

  3. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS

    PLoS ONE, Vol. 10, Núm. 6

  4. Predictors of disability worsening in clinically isolated syndrome

    Annals of Clinical and Translational Neurology, Vol. 2, Núm. 5, pp. 479-491

  5. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

    Annals of Neurology, Vol. 77, Núm. 3, pp. 425-435

2014

  1. Predictors and dynamics of postpartum relapses in women with multiple sclerosis

    Multiple Sclerosis Journal, Vol. 20, Núm. 6, pp. 739-746

  2. Risk of relapse phenotype recurrence in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 20, Núm. 11, pp. 1511-1522

  3. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent

    Annals of Neurology, Vol. 76, Núm. 6, pp. 880-890

2013

  1. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

    PLoS ONE, Vol. 8, Núm. 5

  2. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

    Brain, Vol. 136, Núm. 12, pp. 3609-3617

2012

  1. Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis

    PLoS ONE, Vol. 7, Núm. 10

  2. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: Results from the MSBase Registry

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 83, Núm. 3, pp. 305-310